• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤进化会选择性地使核心 microRNA 机制失活,从而逃避免疫。

Tumor evolution selectively inactivates the core microRNA machinery for immune evasion.

机构信息

Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.

出版信息

Nat Commun. 2021 Dec 1;12(1):7003. doi: 10.1038/s41467-021-27331-3.

DOI:10.1038/s41467-021-27331-3
PMID:34853298
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8636623/
Abstract

Cancer cells acquire genetic heterogeneity to escape from immune surveillance during tumor evolution, but a systematic approach to distinguish driver from passenger mutations is lacking. Here we investigate the impact of different immune pressure on tumor clonal dynamics and immune evasion mechanism, by combining massive parallel sequencing of immune edited tumors and CRISPR library screens in syngeneic mouse tumor model and co-culture system. We find that the core microRNA (miRNA) biogenesis and targeting machinery maintains the sensitivity of cancer cells to PD-1-independent T cell-mediated cytotoxicity. Genetic inactivation of the machinery or re-introduction of ANKRD52 frequent patient mutations dampens the JAK-STAT-interferon-γ signaling and antigen presentation in cancer cells, largely by abolishing miR-155-targeted silencing of suppressor of cytokine signaling 1 (SOCS1). Expression of each miRNA machinery component strongly correlates with intratumoral T cell infiltration in nearly all human cancer types. Our data indicate that the evolutionarily conserved miRNA pathway can be exploited by cancer cells to escape from T cell-mediated elimination and immunotherapy.

摘要

癌细胞在肿瘤进化过程中获得遗传异质性以逃避免疫监视,但缺乏系统的方法来区分驱动突变和乘客突变。在这里,我们通过在同种小鼠肿瘤模型和共培养系统中结合免疫编辑肿瘤的大规模平行测序和 CRISPR 文库筛选,研究了不同免疫压力对肿瘤克隆动态和免疫逃逸机制的影响。我们发现核心 microRNA (miRNA) 生物发生和靶向机制保持了癌细胞对 PD-1 非依赖性 T 细胞介导的细胞毒性的敏感性。该机制的遗传失活或 ANKRD52 频繁患者突变的重新引入削弱了癌细胞中的 JAK-STAT-干扰素-γ信号和抗原呈递,主要是通过消除 miR-155 靶向沉默细胞因子信号转导抑制因子 1 (SOCS1)。几乎所有人类癌症类型中,每种 miRNA 机制成分的表达都与肿瘤内 T 细胞浸润强烈相关。我们的数据表明,进化保守的 miRNA 途径可被癌细胞利用,以逃避 T 细胞介导的消除和免疫治疗。

相似文献

1
Tumor evolution selectively inactivates the core microRNA machinery for immune evasion.肿瘤进化会选择性地使核心 microRNA 机制失活,从而逃避免疫。
Nat Commun. 2021 Dec 1;12(1):7003. doi: 10.1038/s41467-021-27331-3.
2
SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.SOX2 促进了 PD-L1 高表达的黑色素瘤对 T 细胞介导的细胞毒性的耐药性,而 SAHA 可以逆转这种耐药性。
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001037.
3
Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.在T细胞特异性微小RNA-155缺陷型小鼠中,抗肿瘤免疫存在缺陷,而免疫检查点阻断可挽救这种缺陷。
J Biol Chem. 2017 Nov 10;292(45):18530-18541. doi: 10.1074/jbc.M117.808121. Epub 2017 Sep 14.
4
IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies.IRAK1 调控的 IFN-γ 信号诱导 MDSC 促进 FGFR1 驱动的血液系统恶性肿瘤中的免疫逃逸。
Mol Cancer. 2021 Dec 14;20(1):165. doi: 10.1186/s12943-021-01460-1.
5
Effect of microRNA-155 on the interferon-gamma signaling pathway in biliary atresia.微小RNA-155对胆道闭锁中γ-干扰素信号通路的影响。
Chin J Physiol. 2016 Dec 31;59(6):315-322. doi: 10.4077/CJP.2016.BAE419.
6
Functional genomic landscape of cancer-intrinsic evasion of killing by T cells.肿瘤细胞内在逃避 T 细胞杀伤的功能基因组景观
Nature. 2020 Oct;586(7827):120-126. doi: 10.1038/s41586-020-2746-2. Epub 2020 Sep 23.
7
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.嵌合抗原受体工程化 NK 细胞免疫疗法克服了 T 细胞逃逸变异癌细胞的选择。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002128.
8
Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.PD-1 和 PD-L1 联合阻断促进胰腺导管腺癌中持久的新抗原特异性 T 细胞介导的免疫。
Cell Rep. 2019 Aug 20;28(8):2140-2155.e6. doi: 10.1016/j.celrep.2019.07.059.
9
MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene.MicroRNA-155 在乳腺癌中作为一种癌基因发挥作用,其靶基因是细胞因子信号转导抑制因子 1。
Cancer Res. 2010 Apr 15;70(8):3119-27. doi: 10.1158/0008-5472.CAN-09-4250. Epub 2010 Mar 30.
10
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.ILT4 抑制可预防 TAM 和功能失调 T 细胞介导的免疫抑制,并增强 EGFR 激活的 NSCLC 中抗 PD-L1 治疗的疗效。
Theranostics. 2021 Jan 19;11(7):3392-3416. doi: 10.7150/thno.52435. eCollection 2021.

引用本文的文献

1
The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.新抗原和肿瘤突变负荷在癌症免疫治疗中的作用:进展、机制及展望
J Hematol Oncol. 2025 Sep 2;18(1):84. doi: 10.1186/s13045-025-01732-z.
2
Clinical Relevance of , , , and Gene Expression and Genetic Variants in HPV-Negative Oral Carcinomas.人乳头瘤病毒阴性口腔癌中、、、基因表达及基因变异的临床相关性
Int J Mol Sci. 2025 Jul 25;26(15):7218. doi: 10.3390/ijms26157218.
3
Recent research advances in interleukin, microRNA and neuroendocrine tumor biomarkers (Review).

本文引用的文献

1
Interferon-γ: teammate or opponent in the tumour microenvironment?干扰素-γ:肿瘤微环境中的队友还是对手?
Nat Rev Immunol. 2022 Mar;22(3):158-172. doi: 10.1038/s41577-021-00566-3. Epub 2021 Jun 21.
2
Dicer represses the interferon response and the double-stranded RNA-activated protein kinase pathway in mouse embryonic stem cells.Dicer 抑制干扰素反应和双链 RNA 激活的蛋白激酶途径在小鼠胚胎干细胞中。
J Biol Chem. 2021 Jan-Jun;296:100264. doi: 10.1016/j.jbc.2021.100264. Epub 2021 Jan 8.
3
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.
白细胞介素、微小RNA与神经内分泌肿瘤生物标志物的最新研究进展(综述)
Mol Clin Oncol. 2025 Jun 17;23(2):71. doi: 10.3892/mco.2025.2866. eCollection 2025 Aug.
4
Cyclosporine A Accelerates Neurorecovery Transcriptional Trajectory in a Swine Model of Diffuse Traumatic Brain Injury.环孢素A在弥漫性创伤性脑损伤猪模型中加速神经恢复转录轨迹。
Int J Mol Sci. 2025 Apr 9;26(8):3531. doi: 10.3390/ijms26083531.
5
Transcriptome Analyses Reveal the Important miRNAs Involved in Immune Response of Gastric Cancer.转录组分析揭示参与胃癌免疫反应的重要微小RNA
IET Syst Biol. 2025 Jan-Dec;19(1):e70014. doi: 10.1049/syb2.70014.
6
Evaluation and Library Expansion of Small Molecule MHC-I Inducers.小分子MHC-I诱导剂的评估与文库扩展
bioRxiv. 2025 Feb 5:2025.01.31.635109. doi: 10.1101/2025.01.31.635109.
7
A tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses.肿瘤条件性白细胞介素-15与免疫疗法安全协同作用,以增强抗肿瘤免疫反应。
Mol Ther. 2024 Dec 4;32(12):4482-4496. doi: 10.1016/j.ymthe.2024.10.021. Epub 2024 Oct 28.
8
SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity.SOCS1 是免疫稳态、炎症和肿瘤免疫中的一个关键检查点。
Front Immunol. 2024 Jun 14;15:1419951. doi: 10.3389/fimmu.2024.1419951. eCollection 2024.
9
Clinical and Immunological Significance of ANKRD52 in Pan-Cancer.ANKRD52 在泛癌中的临床和免疫学意义。
Biochem Genet. 2024 Dec;62(6):4335-4358. doi: 10.1007/s10528-023-10645-w. Epub 2024 Jan 31.
10
Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy.拼接新抗原发现与 SNAF 揭示癌症免疫治疗的共同靶点。
Sci Transl Med. 2024 Jan 17;16(730):eade2886. doi: 10.1126/scitranslmed.ade2886.
肿瘤和 T 细胞内在机制对检查点抑制敏感性的荟萃分析。
Cell. 2021 Feb 4;184(3):596-614.e14. doi: 10.1016/j.cell.2021.01.002. Epub 2021 Jan 27.
4
The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression.利用基因表达的小鼠微环境细胞群体计数方法来估计小鼠样本中组织浸润免疫和基质细胞群体的丰度。
Genome Med. 2020 Oct 6;12(1):86. doi: 10.1186/s13073-020-00783-w.
5
Functional genomic landscape of cancer-intrinsic evasion of killing by T cells.肿瘤细胞内在逃避 T 细胞杀伤的功能基因组景观
Nature. 2020 Oct;586(7827):120-126. doi: 10.1038/s41586-020-2746-2. Epub 2020 Sep 23.
6
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.CRISPR-GEMM 高通量诱变筛选鉴定 KMT2D 为免疫检查点阻断的主要调控因子。
Cancer Discov. 2020 Dec;10(12):1912-1933. doi: 10.1158/2159-8290.CD-19-1448. Epub 2020 Sep 4.
7
Glioma escape signature and clonal development under immune pressure.免疫压力下的神经胶质瘤逃逸特征和克隆演化。
J Clin Invest. 2020 Oct 1;130(10):5257-5271. doi: 10.1172/JCI138760.
8
Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors.利用 CRISPR-Cas 核酸酶、碱基编辑器、转座酶和 Prime 编辑器进行基因组编辑。
Nat Biotechnol. 2020 Jul;38(7):824-844. doi: 10.1038/s41587-020-0561-9. Epub 2020 Jun 22.
9
TIMER2.0 for analysis of tumor-infiltrating immune cells.TIMER2.0 用于分析肿瘤浸润免疫细胞。
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514. doi: 10.1093/nar/gkaa407.
10
Uncovering the cellular capacity for intensive and specific feedback self-control of the argonautes and MicroRNA targeting activity.揭示了 Argonautes 和 MicroRNA 靶向活性的密集且特异性反馈自我控制的细胞能力。
Nucleic Acids Res. 2020 May 21;48(9):4681-4697. doi: 10.1093/nar/gkaa209.